Rabab Nasrallah

Rabab Nasrallah, PhD, has extensive experience in investment and biotechnology, currently serving as an Investment Professional at Earlybird Venture Capital since January 2020. Additionally, Rabab Nasrallah holds multiple board observer and director roles at companies including Prothea Technologies, Grey Wolf Therapeutics, ImCheck Therapeutics, and Priothera SAS. Prior to these positions, Rabab Nasrallah worked as a Program Manager at INCUBATE and served as a Strategy Research Associate at The George Institute for Global Health. Academic credentials include a PhD in Stem Cell and Developmental Biology from UNSW, complemented by postdoctoral research roles at the University of Cambridge and The University of Manchester.